FINWIRES · TerminalLIVE
FINWIRES

研究快讯:American Homes 4 Rent 发布的 2026 年第一季度业绩喜忧参半

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下: AMH公布2025年第四季度每股FFO为0.47美元,与市场预期一致;尽管租金上涨推动营收增长4.2%,但4.55亿美元的营收仍低于预期。平均入住率下降30个基点至95.0%,综合租金增长率从第三季度的3.6%放缓至2.8%,表明在充满挑战的租赁市场中,定价能力有所减弱。管理层大幅下调了2026年核心NOI增长预期,仅为1.0%-3.0%,低于2025年初的预期,理由是经济形势不明朗。该信托基金保持着稳健的资产负债表,总债务为52亿美元,2028年之前无到期债务,平均到期期限为8.5年。 AMH计划在2026年投资5亿至6亿美元用于物业收购,并投资1.5亿至2.5亿美元用于开发,同时还将回购1.15亿美元的股票。我们认为,令人失望的业绩指引和租赁增长放缓表明公司运营面临越来越大的阻力,但其稳健的资产负债表和审慎的资本配置在短期内提供了一定的稳定性。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661